

Perspectives on the treatment of HER2-negative gBRCAm early breast cancer

Thursday, 11 May 2023

18:30 – 19:30 (CEST)

Munich Hall • hub27
Berlin, Germany

Chair



Peter Fasching
University Hospital -
Erlangen
Erlangen, Germany

Faculty



Rupert Bartsch
Medical University
of Vienna
Vienna, Austria



Karen Gelmon
BC Cancer - University
of British Columbia
Vancouver,
British Columbia, Canada

Chair: Peter Fasching (Germany)

AGENDA

| | |
|---------------|---|
| 18:30 – 18:35 | Introduction and objectives <i>Peter Fasching</i> |
| 18:35 – 18:55 | Evolving treatment landscape in HER2-gBRCAm patients <i>Karen Gelmon</i> |
| 18:55 – 19:10 | Patient case study <i>Rupert Bartsch</i> |
| 19:10 – 19:25 | Q&A <i>Faculty</i> |
| 19:25 – 19:30 | Closing remarks <i>Peter Fasching</i> |

Agenda may be subject to change pending speaker confirmation